{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:55:24Z","timestamp":1788580524377,"version":"build-2803163510"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974183"],"award-info":[{"award-number":["81974183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFA0108603"],"award-info":[{"award-number":["2018YFA0108603"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.intimp.2023.109895","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T23:14:37Z","timestamp":1676848477000},"page":"109895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity"],"prefix":"10.1016","volume":"117","author":[{"given":"Xiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1496-3145","authenticated-orcid":false,"given":"Yiqiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1760-4009","authenticated-orcid":false,"given":"Wei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2023.109895_b0005","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.intimp.2023.109895_b0010","first-page":"482","article-title":"Cardiovascular toxicity of biologic agents for cancer therapy","volume":"28","author":"Bhave","year":"2014","journal-title":"Oncology (Williston Park)"},{"issue":"36","key":"10.1016\/j.intimp.2023.109895_b0015","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"issue":"18","key":"10.1016\/j.intimp.2023.109895_b0020","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1089\/ars.2016.6930","article-title":"From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview","volume":"30","author":"Tocchetti","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.intimp.2023.109895_b0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of Anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"issue":"5","key":"10.1016\/j.intimp.2023.109895_b0030","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2174\/1568009618666171129222159","article-title":"Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity","volume":"19","author":"An","year":"2019","journal-title":"Curr. Cancer Drug Targets."},{"issue":"3","key":"10.1016\/j.intimp.2023.109895_b0035","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/eci.12589","article-title":"Update on cardiotoxicity of anti-cancer treatments","volume":"46","author":"Rosa","year":"2016","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.intimp.2023.109895_b0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2016.11.174","article-title":"Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond","volume":"227","author":"Di Lisi","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109895_b0045","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos","year":"2009","journal-title":"Acta Oncol."},{"key":"10.1016\/j.intimp.2023.109895_b0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/CMAR.S74202","article-title":"Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma","volume":"7","author":"Gunnarsson","year":"2015","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.intimp.2023.109895_b0055","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.2147\/OTT.S170138","article-title":"Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities","volume":"11","author":"Chaar","year":"2018","journal-title":"Onco Targets Ther."},{"issue":"21","key":"10.1016\/j.intimp.2023.109895_b0060","doi-asserted-by":"crossref","first-page":"e6979","DOI":"10.1097\/MD.0000000000006979","article-title":"Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib: A case report and literature review","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.intimp.2023.109895_b0065","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/cas.13977","article-title":"Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan","volume":"110","author":"Masuda","year":"2019","journal-title":"Cancer Sci."},{"issue":"16","key":"10.1016\/j.intimp.2023.109895_b0070","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jacc.2018.02.038","article-title":"Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors: It Is Now Time for Cardio-Immuno-Oncology","volume":"71","author":"Tocchetti","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.intimp.2023.109895_b0075","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ebiom.2017.05.024","article-title":"Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity","volume":"21","author":"Chen-Scarabelli","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2023.109895_b0080","doi-asserted-by":"crossref","unstructured":"Rhea IB, Oliveira GH. Cardiotoxicity of Novel Targeted Chemotherapeutic Agents. Curr Treat Options Cardiovasc Med. (2018) 20(7): 53. doi:10.1007\/s11936-018-0649-4.","DOI":"10.1007\/s11936-018-0649-4"},{"key":"10.1016\/j.intimp.2023.109895_b0085","doi-asserted-by":"crossref","unstructured":"Siegel D, Martin T, Nooka A, Harvey R D, Vij R, Niesvizky R, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. (2013) 98(11):1753-61. doi:10.3324\/haematol.2013.089334Gordon L I, Burke M A, Singh A T, Prachand S, Lieberman E D, Sun L, et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem. (2009) 284(4):2080-7. doi:10.1074\/jbc.M804570200.","DOI":"10.3324\/haematol.2013.089334"},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0090","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/jmcc.1998.0862","article-title":"Age-related decrease in cardiac tolerance to oxidative stress","volume":"31","author":"Abete","year":"1999","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"5","key":"10.1016\/j.intimp.2023.109895_b0095","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.intimp.2023.109895_b0100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.yjmcc.2004.12.013","article-title":"Apoptosis-modulating interaction of the neuregulin\/erbB pathway with anthracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes","volume":"38","author":"Rohrbach","year":"2005","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.intimp.2023.109895_b0105","doi-asserted-by":"crossref","first-page":"7582730","DOI":"10.1155\/2018\/7582730","article-title":"Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib","volume":"2018","author":"Gorini","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.intimp.2023.109895_b0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1471-2407-8-129","article-title":"Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways","volume":"8","author":"Siddiqa","year":"2008","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2023.109895_b0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MAJ.0000000000000549","article-title":"Cardiac Adrenergic Nervous System and Left Ventricular Remodeling","volume":"350","author":"Samson","year":"2015","journal-title":"Am. J. Med. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2023.109895_b0120","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/01.CIR.0000138109.32748.80","article-title":"Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion","volume":"110","author":"Okoshi","year":"2004","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.intimp.2023.109895_b0125","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","article-title":"Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes","volume":"15","author":"Mohan","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0130","article-title":"Implications of Autophagy and Oxidative Stress in Trastuzumab-Mediated Cardiac Toxicities","volume":"2","author":"Mohan","year":"2017","journal-title":"Austin Pharmacol Pharm."},{"key":"10.1016\/j.intimp.2023.109895_b0135","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2019.20138","article-title":"The role of autophagy in HER2-targeted therapy","volume":"149","author":"Janser","year":"2019","journal-title":"Swiss Med. Wkly."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2023.109895_b0140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11010-012-1395-7","article-title":"Neuregulin-1 suppresses cardiomyocyte apoptosis by activating PI3K\/Akt and inhibiting mitochondrial permeability transition pore","volume":"370","author":"Jie","year":"2012","journal-title":"Mol. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.intimp.2023.109895_b0145","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ctrv.2010.09.001","article-title":"Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis","volume":"37","author":"Chen","year":"2011","journal-title":"Cancer Treat. Rev."},{"issue":"9712","key":"10.1016\/j.intimp.2023.109895_b0150","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2023.109895_b0155","first-page":"70","article-title":"Trastuzumab-induced cardiac dysfunction: A 'dual-hit'","volume":"16","author":"Zeglinski","year":"2011","journal-title":"Exp. Clin. Cardiol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109895_b0160","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10557-021-07181-3","article-title":"The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review","volume":"36","author":"Wu","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"3","key":"10.1016\/j.intimp.2023.109895_b0165","doi-asserted-by":"crossref","first-page":"R230","DOI":"10.1152\/ajpregu.00373.2015","article-title":"Endothelin-1 and antiangiogenesis","volume":"310","author":"Lankhorst","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.intimp.2023.109895_b0170","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/5584_2016_90","article-title":"Endothelial Dysfunction and Hypertension","volume":"956","author":"Konukoglu","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.intimp.2023.109895_b0175","doi-asserted-by":"crossref","unstructured":"Steeghs N, Rabelink T J, op 't Roodt J, Batman E, Cluitmans F H, Weijl N I, et al. Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol. (2010) 21(5):1100-5. doi:10.1093\/annonc\/mdp417.","DOI":"10.1093\/annonc\/mdp417"},{"issue":"6","key":"10.1016\/j.intimp.2023.109895_b0180","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J. Am. Soc. Hypertens."},{"issue":"2","key":"10.1016\/j.intimp.2023.109895_b0185","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.intimp.2023.109895_b0190","doi-asserted-by":"crossref","first-page":"9616","DOI":"10.1002\/jcp.27648","article-title":"VEGF-C attenuates renal damage in salt-sensitive hypertension","volume":"234","author":"Beaini","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"4","key":"10.1016\/j.intimp.2023.109895_b0195","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/HYPERTENSIONAHA.117.10490","article-title":"VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes","volume":"71","author":"Neves","year":"2018","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.intimp.2023.109895_b0200","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1172\/JCI24682","article-title":"Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure","volume":"115","author":"Shiojima","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2023.109895_b0205","first-page":"719","article-title":"Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials","volume":"7","author":"Kim","year":"2014","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.intimp.2023.109895_b0210","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/cvr\/cvz035","article-title":"Common risk factors for heart failure and cancer","volume":"115","author":"Meijers","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.intimp.2023.109895_b0215","doi-asserted-by":"crossref","unstructured":"Mercurio V, Cuomo A, Cadeddu Dessalvi C, Deidda M, Di Lisi D, Novo G, et al. Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC). Antioxidants (Basel). (2020) 9(7). doi:10.3390\/antiox9070641.","DOI":"10.3390\/antiox9070641"},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1752-8062.2008.00090.x","article-title":"Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase","volume":"2","author":"Kerkela","year":"2009","journal-title":"Clin. Transl. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2023.109895_b0225","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0230","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/157016110790226660","article-title":"Thromboembolic events in patients treated with anti-angiogenic drugs","volume":"8","author":"Ferroni","year":"2010","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"12","key":"10.1016\/j.intimp.2023.109895_b0235","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2023.109895_b0240","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jjcc.2009.03.009","article-title":"Sorafenib-induced acute myocardial infarction due to coronary artery spasm","volume":"54","author":"Arima","year":"2009","journal-title":"J. Cardiol."},{"issue":"11","key":"10.1016\/j.intimp.2023.109895_b0245","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11883-017-0678-6","article-title":"Oxidative Stress in Atherosclerosis","volume":"19","author":"Kattoor","year":"2017","journal-title":"Curr. Atheroscler. Rep."},{"issue":"9","key":"10.1016\/j.intimp.2023.109895_b0250","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2174\/0929867325666180508100950","article-title":"Role of Ox-LDL and LOX-1 in Atherogenesis","volume":"26","author":"Kattoor","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0255","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/CIRCRESAHA.116.303975","article-title":"Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels","volume":"116","author":"Ballou","year":"2015","journal-title":"Circ. Res."},{"issue":"11","key":"10.1016\/j.intimp.2023.109895_b0260","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41401-018-0062-2","article-title":"Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity","volume":"39","author":"Zhang","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"issue":"21","key":"10.1016\/j.intimp.2023.109895_b0265","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1161\/CIRCULATIONAHA.117.029626","article-title":"Cardiac Toxicity of Immune Checkpoint Inhibitors: Cardio-Oncology Meets Immunology","volume":"136","author":"Varricchi","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2023.109895_b0270","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2020.08.033","article-title":"Cardiotoxic mechanisms of cancer immunotherapy - A systematic review","volume":"323","author":"Lobenwein","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"10.1016\/j.intimp.2023.109895_b0275","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/79766","article-title":"RasGRP is essential for mouse thymocyte differentiation and TCR signaling","volume":"1","author":"Dower","year":"2000","journal-title":"Nat. Immunol."},{"issue":"15","key":"10.1016\/j.intimp.2023.109895_b0280","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2010-08-300731","article-title":"Negative regulation of mTOR activation by diacylglycerol kinases","volume":"117","author":"Gorentla","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2023.109895_b0285","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1:PD-L1\/2 Pathway from Discovery to Clinical Implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109895_b0290","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3892\/ijmm_00000356","article-title":"Proteasome inhibitor MG132 suppresses number and function of endothelial progenitor cells: involvement of nitric oxide synthase inhibition","volume":"25","author":"Hu","year":"2010","journal-title":"Int. J. Mol. Med."},{"issue":"5","key":"10.1016\/j.intimp.2023.109895_b0295","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.ijrobp.2018.01.001","article-title":"Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment","volume":"100","author":"Kong","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"21","key":"10.1016\/j.intimp.2023.109895_b0300","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1111\/bph.13643","article-title":"Trastuzumab cardiotoxicity: from clinical trials to experimental studies","volume":"174","author":"Nemeth","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2023.109895_b0305","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00395-016-0576-z","article-title":"ErbB2 signaling at the crossing between heart failure and cancer","volume":"111","author":"Vermeulen","year":"2016","journal-title":"Basic Res. Cardiol."},{"issue":"4","key":"10.1016\/j.intimp.2023.109895_b0310","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/HCO.0000000000000637","article-title":"Cardiotoxicity of HER2-targeted therapies","volume":"34","author":"Copeland-Halperin","year":"2019","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.intimp.2023.109895_b0315","doi-asserted-by":"crossref","unstructured":"Tan-Chiu E, Yothers G, Romond E, Geyer C E, Jr., Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. (2005) 23(31):7811-9. doi:10.1200\/JCO.2005.02.4091.","DOI":"10.1200\/JCO.2005.02.4091"},{"issue":"5","key":"10.1016\/j.intimp.2023.109895_b0320","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0325","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00280-018-3593-9","article-title":"Sunitinib does not acutely alter left ventricular systolic function, but induces diastolic dysfunction","volume":"82","author":"Wada","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9604","key":"10.1016\/j.intimp.2023.109895_b0330","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.intimp.2023.109895_b0335","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","article-title":"Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval)","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf."},{"issue":"11","key":"10.1016\/j.intimp.2023.109895_b0340","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.bulcan.2015.09.001","article-title":"Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria","volume":"102","author":"Launay-Vacher","year":"2015","journal-title":"Bull. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2023.109895_b0345","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2023.109895_b0350","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.intimp.2023.109895_b0355","doi-asserted-by":"crossref","unstructured":"Lynch D R, Jr., Kickler T S, Rade J J. Recurrent myocardial infarction associated with gefitinib therapy. J. Thromb Thrombolysis. (2011) 32(1):120-4. doi:10.1007\/s11239-010-0539-4.","DOI":"10.1007\/s11239-010-0539-4"},{"issue":"5","key":"10.1016\/j.intimp.2023.109895_b0360","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9051268","article-title":"Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer","volume":"9","author":"Zaborowska-Szmit","year":"2020","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.109895_b0365","doi-asserted-by":"crossref","first-page":"161","DOI":"10.6004\/jnccn.2013.0024","article-title":"Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers","volume":"11","author":"Yu","year":"2013","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.intimp.2023.109895_b0370","doi-asserted-by":"crossref","unstructured":"Tony Mok M-J A, Ji-Youn Han, Jin Hyoung Kang, Nobuyuki Katakami, HyeRyun Kim, Rachel Hodge, Dana C. Ghiorghiu, Mireille Cantarini, Yi-Long Wu, Vassiliki Papadimitrakopoulou, Marina C Garassino. CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). Journal of Clinical Oncology. (2017) 35:9005. doi:10.1200\/JCO.2017.35.15_suppl.9005.","DOI":"10.1200\/JCO.2017.35.15_suppl.9005"},{"key":"10.1016\/j.intimp.2023.109895_b0375","first-page":"X189","volume":"28","author":"Vansteenkiste","year":"2017","journal-title":"Metastatic"},{"issue":"6","key":"10.1016\/j.intimp.2023.109895_b0380","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/bjc.2015.82","article-title":"Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors","volume":"112","author":"Kloth","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","article-title":"Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib","volume":"2","author":"Kunimasa","year":"2020","journal-title":"JACC CardioOncol."},{"issue":"14","key":"10.1016\/j.intimp.2023.109895_b0390","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.2217\/fon.15.47","article-title":"Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management","volume":"11","author":"Tartarone","year":"2015","journal-title":"Future Oncol."},{"issue":"25","key":"10.1016\/j.intimp.2023.109895_b0395","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.intimp.2023.109895_b0400","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0405","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cllc.2019.06.012","article-title":"ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)","volume":"21","author":"Chiari","year":"2020","journal-title":"Clin. Lung Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2023.109895_b0410","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12032-017-1012-4","article-title":"Lung cancer as a cardiotoxic state: a review","volume":"34","author":"Perez-Callejo","year":"2017","journal-title":"Med. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109895_b0415","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00280-017-3253-5","article-title":"Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies","volume":"79","author":"Morcos","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.intimp.2023.109895_b0420","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.intimp.2023.109895_b0425","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2023.109895_b0430","doi-asserted-by":"crossref","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open."},{"issue":"12","key":"10.1016\/j.intimp.2023.109895_b0435","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"issue":"16","key":"10.1016\/j.intimp.2023.109895_b0440","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10124","key":"10.1016\/j.intimp.2023.109895_b0445","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.intimp.2023.109895_b0450","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.intimp.2023.109895_b0455","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2023.109895_b0460","first-page":"CD010816","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.intimp.2023.109895_b0465","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11912-020-00931-w","article-title":"Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management","volume":"22","author":"Wu","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0470","doi-asserted-by":"crossref","first-page":"e87671","DOI":"10.1371\/journal.pone.0087671","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2023.109895_b0475","doi-asserted-by":"crossref","unstructured":"Jacob P Laubach J F S M, Pieter Sonneveld, Robert Z. Orlowski, Philippe Moreau, Laura Rosi\u00f1ol, Javid J Moslehi, Edward A Faber, Peter M Voorhees, Loreta Marquez, Avinash Desai, Helgi van de Velde, Jennifer Elliott, Hongliang Shi, Edward Dow, Nishith Jobanputra, Dixie-Lee Esseltine, Liviu Niculescu, Kenneth C Anderson, Sagar Lonial, Paul G Richardson. Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM). Blood. (2013) 122(21):3187. doi:10.1182\/blood.v122.21.3187.3187.","DOI":"10.1182\/blood.V122.21.3187.3187"},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0480","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/ejh.12677","article-title":"'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors","volume":"97","author":"Danhof","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0485","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41467-017-01855-z","article-title":"Galphai is required for carvedilol-induced beta1 adrenergic receptor beta-arrestin biased signaling","volume":"8","author":"Wang","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0490","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12012-015-9356-5","article-title":"Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-kappaB, Hypertrophic Gene Expression and Oxidative Stress","volume":"17","author":"Imam","year":"2017","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.intimp.2023.109895_b0495","unstructured":"WHO. The use of the WHO-UMC system for standardised case causality assessment. 2018 [cited 2022; Available from: http:\/\/www.WHO-UMC.org\/graphics\/24734.pdf."},{"issue":"3","key":"10.1016\/j.intimp.2023.109895_b0500","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/14737159.2017.1283219","article-title":"Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy","volume":"17","author":"Cardinale","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"3","key":"10.1016\/j.intimp.2023.109895_b0505","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/1871529X19666181205100705","article-title":"Carfilzomib: A Tale of a Heartbreaking Moment: Case Report and Concise Review of the Literature","volume":"19","author":"Serra","year":"2019","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets"},{"key":"10.1016\/j.intimp.2023.109895_b0510","first-page":"1816287","article-title":"The First Autopsy Case of Fatal Acute Cardiac Failure after Administration of Carfilzomib in a Patient with Multiple Myeloma","volume":"2019","author":"Takakuwa","year":"2019","journal-title":"Case Rep Hematol."},{"issue":"14","key":"10.1016\/j.intimp.2023.109895_b0515","doi-asserted-by":"crossref","first-page":"e15036","DOI":"10.1097\/MD.0000000000015036","article-title":"Cardiac amyloidosis as a rare cause of heart failure: A case report","volume":"98","author":"Gao","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0520","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000513002","article-title":"Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases","volume":"14","author":"Ito","year":"2021","journal-title":"Case Rep Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109895_b0525","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1634\/theoncologist.2018-0285","article-title":"Takotsubo Cardiomyopathy During Anti-HER2 Therapy for Metastatic Breast Cancer","volume":"24","author":"Lees","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2023.109895_b0530","doi-asserted-by":"crossref","unstructured":"Tanaka S, Ikari A, Nitta T, Horiuchi T. Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors. Oxf Med Case Reports. (2017) 2017(7):omx038. doi:10.1093\/omcr\/omx038.","DOI":"10.1093\/omcr\/omx038"},{"issue":"6","key":"10.1016\/j.intimp.2023.109895_b0535","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J. Hypertens."},{"issue":"5","key":"10.1016\/j.intimp.2023.109895_b0540","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2023.109895_b0545","first-page":"22:74","article-title":"Growth Factor (VEGF) Inhibitor Cardiotoxicity: What Should We Know?","author":"Teresa L\u00f3pez-Fern\u00e1ndez","year":"2020","journal-title":"Curr Treat Options Cardio Med."},{"key":"10.1016\/j.intimp.2023.109895_b0550","doi-asserted-by":"crossref","unstructured":"Izumida T, Imamura T, Ueno Y, Fukahara K, Kinugawa K. Acute Heart Failure in a Patient with Occult Barlow's Disease Receiving Bevacizumab. Medicina (Kaunas). (2021) 57(10). doi:10.3390\/medicina57100998.","DOI":"10.3390\/medicina57100998"},{"issue":"10","key":"10.1016\/j.intimp.2023.109895_b0555","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice","volume":"117","author":"Gotsman","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.intimp.2023.109895_b0560","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.intimp.2023.109895_b0565","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2119\/molmed.2011.00471","article-title":"Statins induce the accumulation of regulatory T cells in atherosclerotic plaque","volume":"18","author":"Meng","year":"2012","journal-title":"Mol. Med."},{"issue":"6","key":"10.1016\/j.intimp.2023.109895_b0570","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.ATV.13.6.892","article-title":"Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits. Possible mechanisms","volume":"13","author":"Asai","year":"1993","journal-title":"Arterioscler Thromb."},{"issue":"6","key":"10.1016\/j.intimp.2023.109895_b0575","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","article-title":"Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis","volume":"134","author":"Carrier","year":"2014","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.intimp.2023.109895_b0580","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1378\/chest.14-0402","article-title":"Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis","volume":"147","author":"Vedovati","year":"2015","journal-title":"Chest"},{"issue":"20","key":"10.1016\/j.intimp.2023.109895_b0585","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","article-title":"Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2","volume":"70","author":"Chang","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109895_b0590","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11523-009-0111-3","article-title":"QT interval prolongation among patients treated with angiogenesis inhibitors","volume":"4","author":"Ederhy","year":"2009","journal-title":"Target. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2023.109895_b0595","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ahj.2007.01.040","article-title":"Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes","volume":"153","author":"Gupta","year":"2007","journal-title":"Am. Heart J."},{"issue":"2","key":"10.1016\/j.intimp.2023.109895_b0600","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2023.109895_b0605","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.intimp.2023.109895_b0610","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.2147\/CMAR.S185202","article-title":"Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges","volume":"11","author":"Martin Huertas","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.intimp.2023.109895_b0615","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40164-019-0132-2","article-title":"Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation","volume":"8","author":"Charles","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109895_b0620","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/15563650.2017.1401079","article-title":"Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma","volume":"56","author":"Chen","year":"2018","journal-title":"Clin. Toxicol. (Phila.)"},{"issue":"3","key":"10.1016\/j.intimp.2023.109895_b0625","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/1556-4029.13633","article-title":"Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab","volume":"63","author":"Matson","year":"2018","journal-title":"J. Forensic Sci."},{"issue":"8","key":"10.1016\/j.intimp.2023.109895_b0630","first-page":"1059","article-title":"Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area","volume":"34","author":"Mir","year":"2018","journal-title":"Can. J. Cardiol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0635","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000498985","article-title":"Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2023.109895_b0640","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CJI.0000000000000282","article-title":"Combination Nivolumab\/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature","volume":"42","author":"Khoury","year":"2019","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2023.109895_b0645","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/CJI.0000000000000190","article-title":"Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy","volume":"41","author":"Tajmir-Riahi","year":"2018","journal-title":"J. Immunother."},{"issue":"18","key":"10.1016\/j.intimp.2023.109895_b0650","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:55:31Z","timestamp":1778619331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923002151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":130,"alternative-id":["S1567576923002151"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109895","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109895"}}